To include your compound in the COVID-19 Resource Center, submit it here.

Prevnar 13: Phase III data

The double-blind, U.S. Phase III Study 004 trial in 835 healthy pneumococcal vaccine-naïve adults aged 60-64 showed that a single dose of Prevnar 13 met the primary endpoint by demonstrating non-inferior immunogenicity compared to Pneumovax 23 pneumococcal vaccine for

Read the full 393 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers